Lilly’s Curevo deal turns AAHI’s adjuvant science into a late-stage vaccine opportunity
Find out how AAHI’s SLA-SE adjuvant could shape Lilly’s next-generation shingles vaccine strategy after the Curevo acquisition.
Pharma & Biotech